Esther Guadalupe Corona-Sanchez

Esther Guadalupe Corona-Sanchez

Auto-generated profile, based on publicly available information

Esther Guadalupe Corona-Sanchez

Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatologia y del Sistema Musculo-Esqueletico, Universidad de Guadalajara, Guadalajara, Mexico

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MMMónica Vázquez-Del Mercado
Mónica Vázquez-Del Mercado
LNLourdes Nuñez-Atahualpa
Lourdes Nuñez-Atahualpa
MFMauricio Figueroa-Sánchez
Mauricio Figueroa-Sánchez
EBEduardo Gomez Banuelos
Eduardo Gomez Banuelos
ARAlberto Daniel Rocha-Muñoz
Alberto Daniel Rocha-Muñoz
JAJavier Andrade-Garduño
Javier Andrade-Garduño
The main cause of death in rheumatoid arthritis (RA) is cardiovascular events. We evaluated the relationship of anticyclic citrullinated peptide (anti-CCP) antibody levels with increased carotid intima-media thickness (cIMT) in RA patients.Methods. Forty-five anti-CCP positive and 37 anti-CCP negative RA patients, and 62 healthy controls (HC) were studied. All groups were assessed for atherogenic index of plasma (AIP) and cIMT. Anti-CCP, C-reactive protein (CRP), and levels of tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA).Results. The anti-CCP positive RA patients showed increased cIMT compared to HC and anti-CCP negative (P<0.001). Anti-CCP positive versus anti-CCP negative RA patients, had increased AIP, TNFαand IL-6 (P<0.01), and lower levels of high density lipoprotein cholesterol (HDL-c) (P=0.02). The cIMT correlated with levels of anti-CCP (r=0.513,P=0.001), CRP (r=0.799,P<0.001), TNFα(r=0.642,P=0.001), and IL-6 (r=0.751,P<0.001). In multiple regression analysis, cIMT was associated with CRP (P<0.001) and anti-CCP levels (P=0.03).Conclusions. Levels of anti-CCP and CRP are associated with increased cIMT and cardiovascular risk supporting a clinical role of the measurement of cIMT in RA in predicting and preventing cardiovascular events.

1 January 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
CNC. A. Nava-Valdivia
C. A. Nava-Valdivia
ASA. M. Saldaña-Cruz
A. M. Saldaña-Cruz
ECE. G. Corona-Sanchez
E. G. Corona-Sanchez
JSJessica Murillo Saich
Jessica Murillo Saich
María Cristina Morán MoguelMaría Cristina Morán Moguel
María Cristina Morán Moguel
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
Osteoporosis (OP) is highly prevalent in rheumatoid arthritis (RA) and is influenced by genetic factors. Single-nucleotide polymorphism (SNP) rs2073618 in the TNFRSF11B osteoprotegerin (OPG) gene has been related to postmenopausal OP although, to date, no information has been described concerning whether this polymorphism is implied in abnormalities of bone mineral density (BMD) in RA. We evaluated, in a case-control study performed in Mexican-Mestizo women with RA, whether SNP rs2073618 in the TNFRSF11B gene is associated with a decrease in BMD. RA patients were classified as follows: (1) low BMD and (2) normal BMD. All patients were genotyped for the rs2073618 polymorphism by PCR-RFLP. The frequency of low BMD was 74.4%. Higher age was observed in RA with low BMD versus normal BMD (62 and 54 years, resp.; p<0.001). Worse functioning and lower BMI were observed in RA with low BMD (p=0.003 and p=0.002, resp.). We found similar genotype frequencies in RA with low BMD versus RA with normal BMD (GG genotype 71% versus 64.4%, GC 26% versus 33%, and CC 3% versus 2.2%, resp.; p=0.6). We concluded that in Mexican-Mestizo female patients with RA, the rs2073618 polymorphism of the TNRFS11B gene is not associated with low BMD.

20 April 2021 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
MMMónica Vázquez-Del Mercado
Mónica Vázquez-Del Mercado
EMErika Aurora Martínez-García
Erika Aurora Martínez-García
ADAdrián Daneri-Navarro
Adrián Daneri-Navarro
EBEduardo Gomez Banuelos
Eduardo Gomez Banuelos
BMBeatriz Teresita Martin Marquez
Beatriz Teresita Martin Marquez
MSMinoru Satoh
Minoru Satoh
The presence of myositis-specific antibodies (MSA), was recently reported in healthy individuals, cancer patients without myopathy and paraneoplastic rheumatic syndromes. We sought to analyze the f...

3 February 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HCHeriberto Jacobo Cuevas
Heriberto Jacobo Cuevas
Edsaul Emilio Perez-GuerreroEdsaul Emilio Perez-Guerrero
Edsaul Emilio Perez-Guerrero
ECEsther G. Corona-Sanchez
Esther G. Corona-Sanchez
ERElba M. Romero-Tejeda
Elba M. Romero-Tejeda
STSylvia Elena Totsuka
Sylvia Elena Totsuka
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
There is a significant rate of therapeutic failure in rheumatoid arthritis (RA) patients treated with leflunomide (LEF). This study investigates the utility values of teriflunomide levels (A77 1726) in identifying RA patients who remained with moderate or severe disease activity after the treatment with LEF. In this cross-sectional study, we compared: (a) RA patients who achieved a DAS28-ESR ≤ 3.2, and (b) RA patients who maintained a DAS28-ESR > 3.2 after treatment. ROC curves determined the cut-off of A77 1726 with the better performance to identify patients achieving a DAS28-ESR ≤ 3.2. Of the 115 patients treated with LEF, 69 (60%) remained with moderate/severe disease activity and 46 (40%) achieved low disease activity/remission. Higher A77 1726 levels showed a negative correlation with DAS28-ESR (r = − 0.42, p < 0.001) and other parameters of disease activity. We obtained the following utility values with the cut-off of A77 1726 > 10 µg/mL to identify RA patients who achieved a DAS28-ESR ≤ 3.2: sensitivity of 91.31%; specificity of 73.91%; positive predictive value of 70.00%; and negative predictive value of 92.73%. Serum A77 1726 discriminated between RA patients who remained with moderate/severe disease activity despite the treatment with LEF both as monotherapy and LEF as combo therapy.

8 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Katya Rocío Félix-MurrayKatya Rocío Félix-Murray
Katya Rocío Félix-Murray
JVJhonatan Velador-Mendoza
Jhonatan Velador-Mendoza
MMMiguel Marín-Rosales
Miguel Marín-Rosales
PLPablo C Ortiz Lazareno
Pablo C Ortiz Lazareno
LHLaura Perfinka Herrera-González
Laura Perfinka Herrera-González
Claudia Azucena Palafox-SánchezClaudia Azucena Palafox-Sánchez
Claudia Azucena Palafox-Sánchez
Background/Objectives: The increased frequency of circulating T follicular helper (cTfh) and T peripheral helper (Tph) cells in patients with systemic lupus erythematosus (SLE) and their association with higher disease activity have been reported. However, their role in the immunopathogenesis of SLE remains unclear. CCR2 and CCR5 have been identified on the surface of cTfh and Tph cells in autoimmune diseases such as Sjögren’s Disease. Methods: This study evaluates the association between CCR2+CCR5+cTfh and CCR2+CCR5+Tph cell frequencies and serum cytokine levels in patients with SLE and lupus nephritis (LN). Results: SLE patients showed higher frequencies of cTfh and Tph cells. Overall, CCR2 and CCR5 expression was higher in Tph cells than in cTfh cells. The frequency of CCR5+Tph and CCR5+cTfh cells was higher in patients with proliferative LN than in those with mixed-type LN. IL-21 correlated with the frequency of CCR2+CCR5+ Tph cells. In renal tissue, expression of CD4, CXCR5, CCR5, and CCR2 was more prominent in tubulo-interstitial areas with predominantly chronic lesions. Conclusions: Our results provide information on the expression of CCR2 and CCR5 in cTfh and Tph cells in SLE and offer insights into the association with inducing cytokines, highlighting the potential role of these cells in LN.